Biozen's Cuffless Blood Pressure Tech Vies for Top Prize at Cardiology Summit

OKLAHOMA CITY, OK – March 26, 2026 – An Oklahoma-based digital health company is poised to take center stage at one of the world's premier cardiology events, armed with a technology that could fundamentally change how millions of people monitor their heart health. Biozen, LLC has been named one of four finalists in the American College of Cardiology (ACC) Future Hub Innovation Pitch Challenge, a high-profile competition highlighting transformative technologies in cardiovascular care.

The company will present its novel cuffless blood pressure monitor this Sunday, March 29, at the ACC Scientific Sessions in New Orleans. The selection places Biozen in an elite group of innovators, offering a platform to demonstrate its solution to a critical challenge in modern medicine: making blood pressure measurement simple, accurate, and free from the constraints of the traditional inflatable cuff.

The Quest for a Cuffless Future

For over a century, the sphygmomanometer—the familiar arm cuff—has been the standard for measuring blood pressure. While effective, it is also cumbersome, can be uncomfortable, and provides only a brief snapshot in time. This intermittency can lead to missed diagnoses and incomplete data, as blood pressure fluctuates naturally throughout the day and in response to stress, a phenomenon sometimes called "white coat hypertension" when it occurs in a clinical setting.

The global cuffless blood pressure monitor market, projected to exceed $1.3 billion by 2030, has emerged to address these limitations. The goal is a future where monitoring blood pressure is as passive and continuous as tracking steps or heart rate. However, the path has been fraught with challenges. Many existing cuffless devices, often integrated into smartwatches or rings, have faced skepticism from the medical community regarding their accuracy and reliability. A major hurdle has been the requirement for frequent calibration, where the user must regularly measure their blood pressure with a traditional cuff to keep the cuffless device accurate.

This is the problem Biozen claims to have solved. The company’s technology promises to deliver absolute blood pressure readings without needing a cuff or any form of calibration, a feature that many experts consider the “holy grail” of non-invasive monitoring.

"Being selected as a finalist in the ACC Innovation Pitch Challenge is a meaningful milestone for our team," said Dikran Tourian, Chief Executive Officer of Biozen, in a statement. "We're focused on expanding access to clinically reliable blood pressure measurement without the limitations of traditional cuffs, and we look forward to sharing how our technology can support that at scale."

A New Approach to an Old Problem

Biozen’s solution is embodied in its ultra-compact BP1000 device. Rather than relying on wrist-based sensors, the device measures blood pressure from the digital artery at the fingertip. It combines proprietary pressure and optical sensors with physiologically-informed algorithms to directly measure blood pressure by capturing the pressure at the moment of arterial occlusion. According to the company, this method delivers an absolute measurement grounded in established physiology, not an estimate requiring calibration.

This approach stands in contrast to many existing cuffless technologies that use methods like pulse transit time (PTT), which measures the time it takes for a pulse wave to travel between two points on the body. While promising, PTT-based methods are often susceptible to physiological changes and typically require periodic recalibration to maintain accuracy.

Biozen’s focus on a calibration-free, absolute measurement could be a key differentiator in a crowded and complex market. The company’s platform is protected by a robust intellectual property portfolio of more than 65 granted U.S. and international patents, representing a significant investment and a strategic barrier to competitors.

"ACC brings together clinicians, researchers, innovators and investors who are shaping the future of cardiovascular medicine," stated Omer Inan, PhD, Biozen's Chief Scientific Officer. "We look forward to presenting our approach to blood pressure measurement and the progress of our platform in the Innovation Pitch Challenge."

Navigating the Gauntlet of Validation and Regulation

For any novel medical device, innovation is only half the battle. Gaining the trust of clinicians and regulators requires rigorous scientific proof. Biozen's BP1000 is currently an investigational device, meaning it is not yet cleared by the U.S. Food and Drug Administration (FDA) for commercial sale and its use is limited to clinical studies.

Significantly, the company announced it will present prospective clinical validation data at the ACC conference. These results were gathered by evaluating the device under the ISO 81060-2:2018 validation protocol. This international standard, while traditionally used for automated cuff-based monitors, is a benchmark for accuracy. Adhering to such a stringent protocol signals a deep commitment to clinical validation, a move likely aimed at addressing the widespread expert caution surrounding the cuffless market.

Leading medical bodies, including the American Heart Association, have previously recommended against using cuffless devices for the clinical management of hypertension until their accuracy can be more thoroughly proven. By subjecting its technology to a recognized validation standard and preparing to share the data publicly, Biozen is directly confronting this skepticism.

One industry analyst, speaking on the condition of anonymity, noted the importance of this step. "FDA clearance alone doesn't always guarantee clinical accuracy, which has created confusion for both doctors and patients. A company that comes to the table with transparent, robust validation data against a respected ISO standard is positioning itself to build the trust necessary for widespread adoption."

As Biozen prepares to take the stage in New Orleans, the cardiovascular community will be watching closely. The data presented and the performance in the pitch challenge could offer a pivotal glimpse into the future of hypertension management, determining whether a true revolution in blood pressure monitoring is finally within reach.